Amendment to Merger Agreement for Going-Private Transaction

LakeShore Biopharma Co., Ltd. has entered into Amendment No. 1 to the Agreement and Plan of Merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. This amendment modifies the original merger agreement dated November 4, 2025. The key changes include a reduction in the per share merger consideration from US$0.90 to US$0.066, an extension of the termination date by nine months, and a reduction in termination fees for both parties. The merger, which implies an equity value of approximately US$2.7 million, is expected to close in the third quarter of 2026. The company's board of directors, based on the recommendation of a special committee, has approved the amended agreement. This transaction will result in LakeShore Biopharma becoming a privately held company, with its shares delisted from the OTC Pink Open Market.